UCB Expands its BIMZELX Campaign for the HS Community
UCB, a leading global biopharmaceutical company, is taking significant steps to enhance the awareness of its treatment, BIMZELX, for those affected by hidradenitis suppurativa (HS). The company has announced an extension of its "Get Yourself Back" direct-to-consumer advertising campaign, fundamentally aimed at improving the understanding of HS and BIMZELX.
Campaign Objectives and Community Engagement
This revamped campaign draws inspiration from the insights provided by the HS community. Its primary goal is to raise awareness about BIMZELX and offer a wealth of educational materials. This aims to empower patients to engage in discussions about their treatment options with healthcare providers actively.
Understanding Hidradenitis Suppurativa
HS is a chronic and painful inflammatory skin condition that can lead to significant emotional and physical challenges for those affected. Common symptoms include painful nodules and abscesses, primarily developing in areas where skin rubs together, like the armpits and inner thighs. As a result, individuals often face persistent discomfort and social stigma, making it vital to raise awareness about the condition and available treatment options.
Initiatives Within the BIMZELX Campaign
The "Get Yourself Back" campaign features genuine stories from individuals living with HS. These narratives spotlight their journeys, revealing the struggles they have faced and how they have reclaimed aspects of their lives, including critical emotional and social experiences. By sharing such stories, the campaign seeks to destigmatize HS and promote an open dialogue regarding treatment.
Educational Resources and Support
In addition to captivating TV commercials featuring actual patients, UCB is also offering various educational resources, including interactive videos, tools, and a comprehensive website. This website is equipped with downloadable guides that empower patients to initiate discussions with their healthcare professionals regarding their options and the management of their condition.
Significance of BIMZELX in Treatment
BIMZELX (bimekizumab) stands out as the first and only approved treatment aimed specifically at adults with moderate-to-severe HS. It works by targeting interleukin 17A (IL-17A) and interleukin 17F (IL-17F), key cytokines involved in the inflammatory process. Clinical studies have shown promising results with BIMZELX, noting substantial reductions in the severity of symptoms among patients.
Patient-Centric Approach of UCB
UCB places patients at the core of its operations. This campaign marks a continued commitment to support those living with HS and offers tailored assistance. The BIMZELX Navigate program ensures patients have access to a dedicated Nurse Navigator who helps facilitate their journey through treatment, discusses their goals, and provides updates on their insurance and medication status.
UCB's Vision for Patients
UCB's Head of U.S. Immunology, Camille Lee, emphasizes the company's mission to empower patients with the necessary tools and support to better manage their health. The ongoing expansion of the campaign reflects this dedication and the goal of improving the quality of life for individuals living with HS.
Frequently Asked Questions
What is BIMZELX?
BIMZELX is a treatment specifically designed for adults with moderate-to-severe hidradenitis suppurativa, targeting cytokines involved in inflammation.
How does UCB support patients with HS?
UCB offers the BIMZELX Navigate program, providing tailored support from a Nurse Navigator to ease treatment processes and enhance patient communication with healthcare providers.
Why is awareness important for hidradenitis suppurativa?
Increased awareness can reduce stigma and encourage individuals with HS to seek treatment options, ultimately improving their quality of life.
What is the aim of the "Get Yourself Back" campaign?
The campaign aims to empower the HS community by sharing real patient stories and education on treatment, promoting openness and discussion.
How can the public access information about BIMZELX?
Detailed information, including educational resources and patient stories, can be found on UCB's BIMZELX website.
